Get started

Covidvaccine

PFE Pfizer short term Price TargetWith the new Covid-19 Delta Variant which is more contagious than the other virus strains the question is if you want to get vaccinated or get COVID-19. PFE Pfizer has a great vaccine, a decent P/E Ratio (TTM) of 20.34, pays Forward Dividend & Yield of 1.56 (3.89%) and it is not at all time high like MRNA for example. Expected sales from vaccine in 2021: $15bn-$30bn My short term price target is 44usd. i`m looking forward to read your opinion about it.
NYSE:PFELong
by TopgOptions
6
JNJ - Ascending Triangle + Bad NewsI absolutely hate this company. - Moving averages suggest bullish trend. - 3rd attempt at major resistance. - Doji Candle formed = change in trend/momentum. - "Inside Day" pattern formed = Suggesting a continuation of the current trend. In this situation, it should continue the uptrend for a short period of time until a new pattern/confluence forms. - However, JNJ can't catch a break regarding its vaccine. Issue after issue... - Earnings Report - 7/21 This is a patience play. If you like to jump the gun, you could get burned...but with proper risk management, it may be worth the risk. If you trade options: Aggressive --> Play the Doji this week. 2 week expiration. Moderate --> Wait for a few candles to form after today's doji. 1-2 month expiration. Conservative --> Wait until after earnings. October expiration.
NYSE:JNJ
by PerCent_Investments
MRNA Moderna vs PFE Pfizer | Head and Shoulders patternIf you haven`t longed Moderna with me from here: Then you should realize that the head an shoulders pattern on descending volume of a company that worth 53.402B, but has 747Mil negative earnings for 2020, may lead to $100 per share. On the other hand, undervalued, it`s Pfizer , which has the same amazing results with the vaccine, lots of medicine in the portfolio, a market cap almost 4 times higher, 198.973B and positive earnings of 9.62Bil. The pay also great dividends, btw, 4.38% DIV YIELD on a decent 20.82 P/E ratio . If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:MRNAShort
by TopgOptions
8
Pound falls to 6-week low on soft job numbersThe British pound has recorded considerable losses on Wednesday and fallen below the 1.38 line. Currently, GDP/USD is trading at 1.3775, down 0.63% on the day. The UK released a mixed employment report earlier on Tuesday. In February, claims jumped to 86.6 thousand, compared to the forecast of 9.0 thousand. This was the highest claim count since July. The unemployment rate dropped to 5.0% in January, down from 5.1% beforehand and below the 5.2% expected. There was more positive news from wage growth, which accelerated for a seventh successive month, with a strong gain of 4.8%. Still, investors preferred to focus on the disappointing claimant count and sent the pound to its lowest level since early February. The pound is also under pressure this week from a vaccine spat with the EU. A shortage of AstraZeneca vaccines across Europe has resulted in a threat by the UE to block shipments of the vaccine to the UK. The irony in this situation is that due to the blood-clot scare over the vaccines, Europeans may be reluctant to take the jabs at a time when the EU is busy trying to hoard vaccines and hold up exporting the shots to the UK and elsewhere. A busy week for UK events continues on Wednesday, with the release of inflation data (7:00 CPI). Headline CPI is expected to rise from 0.7% to 0.8%, while Core CPI is projected to remain at 1.4%. The UK vaccination rollout has been proceeding nicely, and with the UK expected to ease lockdown restrictions next week, an increase in economic activity should translate into inflation continuing to pick up speed. 1.3889 has strengthened in resistance, as GBP/USD has declined considerably. GBP/USD is testing support at 1.3782. Below, there is support at 1.3699
by OANDA
Dyadic and Medytox To Develop Vaccines Against COVID-19 VariantsDyadic and Medytox To Develop Vaccines Against COVID-19 Variants Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines) Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox finance.yahoo.com
NASDAQ:DYAI
by AlenCiken
TYME Granted U.S. Patent Claims Treat COVID-19 InfectionsTYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19. Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19. TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication. finance.yahoo.com
T
by AlenCiken
1
Potential Development of an Oral COVID-19l VaccineAeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19. - Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement. to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine. Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19. A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial. finance.yahoo.com Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
A
by AlenCiken
Adamis Surges After Submitting Covid Drug to FDAAdamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls (CMC) and Clinical aspects to be included in the IND. The Company plans to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol. Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. finance.yahoo.com
A
by AlenCiken
1
COVID-19 Wave 2 onset and ongoing... SG, MY, ID and CNAs posted weeks to months ago, it is becoming clearer than daylight that Wave 2 is upon us in 2021. As described previously, the CONFIRMNED charts here have a peciliarity... that the MACD histograms hint of the trend months ahead in advance. As observable, Singapore is currently maanging pretty well, but is heading towards a Wave 2 slowly and surely. The trend is telling us that for the past 16 weeks (4 months) already!!! SG's neighbours Indonesia (lower left) and Malaysia (lower right) have been having trouble keeping the lid on it... with Indonesia experiencing Wave 1.2, and Malaysia in a massive Wave 2. China, top right, had a similar build up to SG and is pretty much in a mild Wave 2 currently. Clearly, showing the path of what to expect as Singapore is heading down the same road. 16 weeks of notice, and nothing solid is being done to stop the wave from reaching. At this rate, by about Chinese New Year, SG should be in Wave 2 proper. In any case, pretty much the whole world is sinking into Wave 2 already... Contrary to the main belief, the vaccine availability, intended to slow down the spread, may actually allow expectations to rise, and a false sense of security to set in... this is where the virus will be taking advantage, as it creates variants, and penetrates through populations So there... INCOMING!
C
by Auguraltrader
2
GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine DevelopmentGeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The Phase 1 grant, titled, “Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,” will support the ongoing design, construction and preclinical testing of GeoVax’s vaccine candidates in preparation for human clinical trials. The efficacy testing will be performed in collaboration with the University of Texas Medical Branch (UTMB). Vaccines using the GV-MVA-VLP platform developed for other pathogens have proven to be efficacious with a single dose, having strong durability which would be a significant advantage for SARS-CoV-2 global vaccination campaigns.” We are pleased to receive this Phase 1 SBIR funding award, which will supplement the internal resources allocated to our COVID-19 vaccine program and accelerate our progress toward human clinical trials. finance.yahoo.com
NASDAQ:GOVX
by AlenCiken
S&P Analysis Week of 12/06/2020: Another Melt Up?The S&P had a good week considering that for most of the week it went sideways to slightly creeping up. Always be weary of creeping markets (they can either stall out and reverse fast or pop to the upside out of nowhere). Are we headed for another leg up (for a potential melt up), are we going to cool-off this week? I do not try to guess which way the market will go and instead I focus on what the market provides me. This week might provide some volatility because in the U.S. the electoral college officially nominates the President and there is the potential for vaccine approval by the FDA. I do not believe the lockdowns, unemployment or the virus will have the same impact as it did in February/March because we know about these things and we expect them to continue into next year. Also, I think the economy has adapted and will continue to adapt as we wait for the vaccine. Lastly, the news is just an excuse to associate something to the stock market. At the end, the market is going to do what it is going to do regardless of the news. Here are two setups that I will be looking for: Trade Setup #1 (buy): This is easy and straight forward. Break above 3700 (with retest) and price will most likely have another leg higher. Above 3700 and it's uncharted territory. Price has no known resistance/support areas. The key here will be to watch as price moves up, how it reacts at certain levels. Taking profit will depend on your personal trading preference. For me, I'll look for 2-3 times my stop loss amount taking profit along the way. Trade Setup #2 (sell) : Price has formed a wedge like structure and this trade tries to capitalize on a break down of the wedge. Although a valid trade, it is not a preferred trade because the trend is your friend until it is not. Technically the chart is bullish at almost every timeframe, so shorting an uptrend is not recommended. However, I will be watching the price action during the week and if I see price vulnerable, I will take this trade. Be cautious with this trade setup because it has less success potential IMO. As mentioned in trade setup 2, price seems to have formed some wedge structure over the last several weeks. These are unpredictable, so it's better to wait to see if price breaks out or down before getting into a trade (with retest). I do not use any indicators or complicated chart patterns because I feel those provide lagging false signals. Instead, I focus on support and resistance lines. This has served me well and has provided me good trade entry signals and profitable trades. Never play the breakout, always wait for the retest and resumption. Breakouts are a losing man's trade because price more times than not, will come back to the breakout/breakdown area for a retest. The retest is your opportunity to pounce. Good luck trading. Don't forget to hit the like button.
CME_MINI:MESZ2020
by XYZ-Trader-
6
ridethepig | Gilead to ATH's with Remdesivir📍 The effect of Remdesivir... The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in. Compare the following two diagrams: Phase III trials & Chinese red carpet Buyers maintaining a strong floor. In the first, you will notice how once we got the break of the channel buyers were allowed to go wandering all the way to the target on grounds of safety! The second wave looks inevitable despite the political fairydust around re-openings, stimulus is running out and now the attempt to reinstate pockets of further lockdowns will make activity immovable. Thus the question, why adding more Gilead? When building a long/short portfolio, we must add hedges and blocks accordingly. The strategic protection with Gilead is pragmatic, 450 million new customers unlocked via European clearance & we already got the ✅ for the red carpet from China. Complacency around the virus is remarkable, UK cheerleading "Super Saturday" and US "Independence Day" ... who would have thought we are in the middle of a pandemic. In any case... An attractive constellation for a swing towards all time highs. Thanks as usual for keeping the feedback coming 👍 or 👎
NASDAQ:GILDLong
by ridethepig
7